Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31957 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Daisuke Hirokawa und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Hauptthemen laut MEDLINE: Methotrexate, Leukoencephalopathies, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Antimetabolites, Antineoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Gefördert von: Kanagawa Prefectural Hospital Pediatric Medical Fund for 2020 and 2021, and KAKENHI, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Background
Methotrexate (MTX)‐induced leukoencephalopathy is a significant neurological complication in pediatric acute lymphoblastic leukemia (ALL) treatment. Magnetic resonance spectroscopy (MRS) is a noninvasive method to assess metabolic changes associated with neurotoxicity. This study aimed to evaluate the diagnostic and prognostic value of MRS‐derived metabolite levels, particularly N ‐acetylaspartate and N ‐acetylaspartylglutamate (tNAA), in MTX‐induced leukoencephalopathy. Procedure We retrospectively analyzed 89 pediatric patients with ALL who underwent brain magnetic resonance imaging (MRI) and MRS at Kanagawa Children's Medical Center between 2009 and 2022. A total of 261 MRS datasets were examined, focusing on metabolic changes in the centrum semiovale. Using mixed logistic regression, we evaluated the association between tNAA levels and leukoencephalopathy onset, as well as their correlation with clinical recovery after MTX discontinuation.
Results
Patients with leukoencephalopathy had significantly lower tNAA levels than those of controls. A predictive model indicated that a 1.0‐point decrease in pretreatment tNAA levels was associated with an approximately 3.22‐fold increase in the odds of developing MTX‐induced leukoencephalopathy. Furthermore, increasing tNAA levels over time were significantly correlated with clinical improvement.
Conclusion
This study suggests that tNAA levels measured using MRS may serve as a potential biomarker for diagnosing and monitoring MTX‐induced leukoencephalopathy. Integrating MRS into clinical assessments may represent a promising future approach to facilitate earlier intervention, inform treatment strategies, and potentially improve patient outcomes, pending validation by future prospective studies. These findings highlight the importance of MRS in the real‐time evaluation of disease progression and therapeutic responses in pediatric patients undergoing MTX treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
- Department of Radiology, Kanagawa Children's Medical Center, Yokohama, Japan.
- Department of Molecular Imaging and Theranostics, National Institute for Quantum and Radiological Science and Technology, Chiba, Japan.
- Department of Radiology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Division of Hematology/Oncology, Department of Pediatrics, Kanagawa Children's Medical Center, Yokohama, Japan.
ORCID-Profile: Masaki Sonoda
Förderung
- Kanagawa Prefectural Hospital Pediatric Medical Fund for 2020 and 2021
- and KAKENHI
- Japan Society for the Promotion of Science
Zitieren
APA
Hirokawa, D., Tomiyasu, M., Sonoda, M., Suenaga, J., Goto, H., Aida, N., & Yamamoto, T. (2025). Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31957
Vancouver
Hirokawa D, Tomiyasu M, Sonoda M, Suenaga J, Goto H, Aida N, et al. Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31957
BibTeX
@article{Hirokawa2025,
author = {Hirokawa, Daisuke and Tomiyasu, Moyoko and Sonoda, Masaki and Suenaga, Jun and Goto, Hiroaki and Aida, Noriko and Yamamoto, Tetsuya},
title = {Metabolite Levels Measured Using Magnetic Resonance Spectroscopy in Pediatric Methotrexate‐Induced Leukoencephalopathy},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31957}
}
EUVIMED